novartis.com

     
Thumbnail of novartis.com
Domain: novartis.com

Found pages about novartis.com

Users that searched for novartis.com

Tweets about novartis.com

  • #CorporateResponsibility is at the core of our care & cure philosophy. Learn more on how we do business responsibly:
  • RT @Novartis: Learn about the latest #Novartis #CML research at #ASH14, Dec 6-9 in San Francisco
  • Long Live Life (Video)
  • @Novartis features innovative #immunotherapy data at #ASH14 and #SABCS14
  • Fingolimod fails to meet endpoints in the INFORMS Phase III trial in primary progressive #MultipleSclerosis (PPMS) -
  • @Novartis features innovative immunotherapy at #ASH14 and #SABCS14
  • Many thanks to #njnpconf sponsor @Novartis!
  • #Novartis #fingolimod disappoints in primary progressive #multiplesclerosis #PPMS
  • RT @MalariaNoMore: #Malaria puts more than 3 billion people at risk, but we're working with @Novartis to help #endmalaria
  • @JaiminPa85 You can read about our indication here:
  • RT @drsophiapathai: Lucentis now licensed to treat pathological myopia: short-sightedness of such a degree to cause damage to the retina ht…
  • Learn about the latest #Novartis #CML research at #ASH14, Dec 6-9 in San Francisco
  • #Fingolimod fails to show disability improvement in primary progressive #MultipleSclerosis via @DrWBRO
  • 【雑記】PARADIGM-HF試験でHFrEFの予後改善作用が認められたアンジオテンシン受容体・NEP阻害薬のLCZ696が，EUにおいて迅速審査の対象に 開発社リリース
  • RT @DrKantor: #MSresearch:@GILENYAGoUSOnly phase 3 INFORMS study in PPMS did not show a significant effect on measure of disability-
  • #MSresearch:@GILENYAGoUSOnly phase 3 INFORMS study in PPMS did not show a significant effect on measure of...
  • #MSresearch:@GILENYAGoUSOnly phase 3 INFORMS study in PPMS did not show a significant effect on measure of disability-
  • RT @cardiobrief: Novartis PR: Novel heart failure drug LCZ696 gets accelerated review in Europe
  • Novartis PR: Novel heart failure drug LCZ696 gets accelerated review in Europe
  • RT @jq1234t: $NVS Gilenya fingolimod missed primary endpoint in PPMS phase 3 study:
  • RT @J_SastreGarriga: Very sad news indeed - fingolimod trial in primary progressive #multiplesclerosis turns out to be negative
  • Novartis: Fingolimod Ph3 Trial in Primary Progressive MS Misses Endpoint More Novartis news at
  • Very sad news indeed - fingolimod trial in primary progressive #multiplesclerosis turns out to be negative
  • $RCPT $NVS Gilenya misses primary endpoint in PPMS
  • $NVS Gilenya fingolimod missed primary endpoint in PPMS phase 3 study:
  • @LisaofSweden Diskuterar ni fortfarande? Här finns FAQ och NVS statement
  • RT @NovartisTurkiye: Novartis'ten yepyeni bir çalışan uygulaması: BlogNot
  • RT @Novartis: EMA approval of #Novartis next-generation therapy based on 2 PhIII #acromegaly trials
  • Novartis'ten yepyeni bir çalışan uygulaması: BlogNot
  • Europe fast-tracks Novartis' heart failure medicine
  • EMA approval of #Novartis next-generation therapy based on 2 PhIII #acromegaly trials
  • Novartis' Heart Failure Drug LCZ696 Gets Accelerated CHMP Assessment More Novartis news at
  • 3-D Printing: Scientists Reinvent Research Tools
  • RT @Novartis: #Novartis treatment approved by EMA to help control hormone levels in #acromegaly
  • #Novartis treatment approved by EMA to help control hormone levels in #acromegaly
  • RT @psicro: Novartis two pivotal Phase III studies in psoriatic #arthritis (PsA) met primary and key secondary endpoints.
  • Extreme sunlight sensitivity is so rare that it was featured in TV series @HOUSEonFOX. See how a real patient coped
  • $NVS FUTURE 1 and FUTURE 2 Phase III studies of AIN457 in psoriatic arthritis met primary and key secondary endpts
  • RT @Novartis: Topline results of pivotal PIII #Novartis studies announced today –first IL17A inhibitor w/ Phase III results in #PsA
  • Topline results of pivotal PIII #Novartis studies announced today –first IL17A inhibitor w/ Phase III results in #PsA
  • Novartis to license Google "smart lens" technology #fb
  • Novartis two pivotal Phase III studies in psoriatic #arthritis (PsA) met primary and key secondary endpoints.
  • .@Novartis presents oncology research & new data at #ESMO14. Release: #ICYMI
  • Novartis: Positive Ph3 Results for AIN457 (secukinumab) in Psoriatic Arthritis More Novartis:
  • RT @Novartis: Top-line results from two multicenter PIII studies from #Novartis in over 1,000 #PsA patients announced today
  • Top-line results from two multicenter PIII studies from #Novartis in over 1,000 #PsA patients announced today
  • "#3DPrinting: Scientists Reinvent Research Tools via @Novartis. cc @ASILifeScience
. ,